CATO Associate Clinical Trial Operations Flashcards
7 cards from real CCA practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 CATO Associate Clinical Trial Operations flashcards as text
Which document provides the most current scientific information about an investigational product and is given to investigators to guide safe use in a clinical trial?
Answer: Investigator Brochure
The Investigator Brochure (IB) compiles all clinical and preclinical data about the investigational product to support safe trial conduct.
In clinical trial supply management, what is 'blinded dispensing' designed to prevent?
Answer: Unintentional unblinding of treatment assignment
Blinded dispensing ensures that neither site staff nor participants can determine treatment assignment from the dispensing process.
What does 'intent-to-treat' (ITT) analysis mean in a clinical trial?
Answer: Analyzing all randomized subjects regardless of protocol adherence or treatment received
ITT analysis includes all randomized participants in the group to which they were assigned, preserving the benefits of randomization.
Which regulatory body in the European Union evaluates Marketing Authorization Applications (MAA) for centralized approval?
Answer: EMA (European Medicines Agency)
The EMA reviews centralized MAAs and provides scientific opinions leading to EU-wide marketing authorizations.
When a clinical monitor identifies a pattern of missing data across multiple subjects at a site, what is the most appropriate first action?
Answer: Document the finding and discuss with the site to identify the root cause
The monitor should document the finding, communicate with site staff, and work to identify and remediate the root cause of missing data.
What is the regulatory significance of the 'Date of First Patient First Visit' (FPFV) in a clinical trial?
Answer: It marks the formal start of the trial and may initiate regulatory reporting timelines
FPFV is considered the trial start date and can trigger regulatory notification requirements and milestone tracking.
In risk-based monitoring (RBM), what determines the frequency and intensity of on-site monitoring visits?
Answer: A risk assessment evaluating site performance, data quality, and patient safety signals
RBM uses a dynamic risk assessment to allocate monitoring resources where risks to data quality and patient safety are greatest.